This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Emergent Biosolutions Secures Contracts Worth Over $250 Million From US Health Department MT
Emergent BioSolutions Inc. Receives $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products CI
Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell Small Cap Completeness Index CI
Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 2000 Index CI
Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 2500 Index CI
Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 3000 Index CI
Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 3000 Value Index CI
Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 2500 Value Index CI
Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell Small Cap Comp Value Index CI
Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 2000 Value Index CI
Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 3000E Value Index CI
Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 3000E Index CI
Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 2000 Dynamic Index CI
Benchmark Adjusts Emergent Biosolutions Price Target to $8 From $5, Maintains Buy Rating MT
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care MT
Top Midday Gainers MT
Wall Street Set to Open Higher Thursday After Fed Holds Rate Steady, Jobless Claims Lower Than Expected MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Earnings Deluge Continues MT
Fed Decision Eases Investor Anxiety as US Futures Trend Higher in Thursday's Premarket MT
Top Premarket Gainers MT
Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Posts Q1 EPS $0.59 MT
Transcript : Emergent BioSolutions Inc., Q1 2024 Earnings Call, May 01, 2024
Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Reports Q1 Revenue $300.4M, vs. Street Est of $224.5M MT
Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2024 CI
Chart Emergent BioSolutions Inc.
More charts
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
7.54 USD
Average target price
8 USD
Spread / Average Target
+6.10%
Consensus
  1. Stock Market
  2. Equities
  3. EBS Stock
  4. News Emergent BioSolutions Inc.
  5. Emergent Biosolutions Secures Contracts Worth Over $250 Million From US Health Department